The Bioinformatics department under Agricultural Engineering and Technology Faculty of Bangladesh Agriculture University (BAU ...

OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced that three of its research abstracts have been accepted for poster ...

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...

Results, highlighted in a poster presentation during the Predictive ... with Serial CTRS could transform the pharma clinical development process from Phase I to Phase III studies,” said George ...

BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the poster presentation ...

An oral presentation will feature ALLO-316, an investigational AlloCAR T product targeting CD70. ALLO-316 is currently being studied in patients with advanced or metastatic renal cell carcinoma (RCC).

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, has announced the presentation of six posters, including one oral ...

Title: ZW1528, a Bispecific Antibody Targeting IL-4Ra and IL-33, Potently Inhibits Key Mediators of Airway Inflammation ...